Literature DB >> 23850524

Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice.

Kinga Sałat1, Katarzyna Kulig, Justyna Gajda, Krzysztof Więckowski, Barbara Filipek, Barbara Malawska.   

Abstract

PURPOSE: The inhibition of plasma membrane GABA transporters (GATs) is responsible for anxiolytic-like, anticonvulsant, antinociceptive and antidepressant-like effects in mice. It also influences animals' motor coordination and their sensitivity to ethanol. The aim of this study was to assess the pharmacological activity of two novel 2-substituted 4-hydroxybutanamides (BM 130 and BM 131) in some screening models. An attempt has been made to establish the relationship between the inhibition of GAT subtype and the observed in vivo activity.
METHODS: The affinity for GAT subtypes was evaluated by means of [(3)H]GABA uptake assay. It indicated that BM 130 inhibited GAT1 and GAT2, whereas BM 131 inhibited GAT1 and GAT3. In mice anxiolytic-like, antidepressant-like, anticonvulsant and antinociceptive properties of the test compounds were assessed. Their influence on motor coordination, locomotor activity and the ability to potentiate effects of subnarcotic doses of ethanol was also tested.
RESULTS: Both compounds administered intraperitoneally exerted a significant anxiolytic-like effect in the four plate test with ED50 values 3.4 and 7.9 mg/kg, respectively. At 30 mg/kg they reduced duration of immobility in the forced swim test for 33% and 19%, respectively. They had no effect on electroconvulsive threshold or pain reactivity in the hot plate assay but they were antinociceptive in the acetic acid-induced writhing test (ED50 values were 12.7 and 18.6 mg/kg, respectively) and in both phases of the formalin test (ED50 values in the first phase were 10.2 and 2.1 mg/kg for BM 130 and BM 131, respectively). No motor adverse effects were observed in mice pretreated with the test compounds in the rotarod or chimney tests but BM 131 caused a transient but statistically significant decrease of animals' locomotor activity.
CONCLUSIONS: In mice BM 130 and BM 131 have anxiolytic-like, antidepressant-like and antinociceptive properties which can be attributed to their affinity for not only mGAT1 but also mGAT2-4.
© 2013.

Entities:  

Keywords:  2-Substituted 4-hydroxybutanamides; Anxiety; ECT; GABA; GATs; MC; MES; Mice; Motor impairments; Pain; Plasma membrane GABA transporters; electroconvulsive threshold; gamma aminobutyric acid; maximal electroshock seizures; methylcellulose; plasma membrane GABA transporters; rotations per minute; rpm

Mesh:

Substances:

Year:  2013        PMID: 23850524     DOI: 10.1016/j.pbb.2013.06.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  L-menthol exhibits antidepressive-like effects mediated by the modification of 5-HTergic, GABAergic and DAergic systems.

Authors:  Weidong Wang; Yuanyuan Jiang; Enbo Cai; Bingchen Li; Yan Zhao; Hongyan Zhu; Lianxue Zhang; Yugang Gao
Journal:  Cogn Neurodyn       Date:  2018-12-11       Impact factor: 5.082

2.  Antipyretic and antinociceptive potential of extract/fractions of Potentilla evestita and its isolated compound, acacetin.

Authors:  Abdur Rauf; Rehan Khan; Haroon Khan; Barkat Ullah; Samreen Pervez
Journal:  BMC Complement Altern Med       Date:  2014-11-18       Impact factor: 3.659

3.  Transcriptomic Analysis of the Effect of GAT-2 Deficiency on Differentiation of Mice Naïve T Cells Into Th1 Cells In Vitro.

Authors:  Xueyan Ding; Yajie Chang; Siquan Wang; Dong Yan; Jiakui Yao; Guoqiang Zhu
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

4.  Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.

Authors:  Kinga Sałat; Anna Furgała; Robert Sałat
Journal:  Inflammopharmacology       Date:  2017-10-25       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.